EACS 15-18. Oktober in Paris

Slides und Poster Gilead Slides und Poster ViiV

Gilead-initiated or Gilead-supported Abstracts Published at EACS 2025

HIV PREVENTION
LENACAPAVIR (LEN)
Oral PS08.5	Ogbuagu,O	Annual Persistence to Twice-Yearly Lenacapavir vs Daily Oral F/TDF for PrEP in the PURPOSE 2 Trial
Oral PS02.4	Molina,JM	Recruitment of Disproportionately Affected Populations in the PURPOSE 5 Study Evaluating Lenacapavir for PrEP in France and the UK Commonly Prescribed Concomitant Medications and Clinical Safety Findings with Lenacapavir for PrEP in PURPOSE 2
Moderated ePoster MeP16.1	Avihingsanon,A	Commonly Prescribed Concomitant Medications and Clinical Safety Findings with Lenacapavir for PrEP in PURPOSE 2
Moderated ePoster MeP16.2	Leleu,H	The Potential Impact of Twice-Yearly Injectable Lenacapavir Among Cisgender Gay, Bisexual, and Other MSM (GBMSM) and Other Priority HIV Prevention Populations (Transgender People and Highly Exposed Heterosexual People) in France
OTHER
Oral O2.7	Onyango,D	Analysis of Barriers to Testing for HIV Prevention and Linkage to Care Among Migrants in Europe
HIV TREATMENT
B/F/TAF
Moderated ePoster MeP21.1	Arora,P	Pharmacokinetics and Safety Data After Switching from Injectable CAB + RPV to oral B/F/TAF
ePoster eP118	Jarrett,J	Treatment Switch Among US Medicare Beneficiaries with HIV
Moderated ePoster MeP05.3	Trottier,B	Five-Year Extended Follow-Up of the Observational BICSTaR Cohort: Final Analysis in PWH Receiving B/F/TAF in Routine Clinical Practice
ePoster eP136	Rockstroh,JK	Treatment Outcomes in People with a Late HIV Diagnosis : A Pooled Analysis of Participants With Advanced HIV Disease at Diagnosis Randomized to Receive B/F/TAF
ePoster eP350	Dunbar,M	HIV Viewpoints: Survey on the Experiences of PWH in Europe
ePoster eP478	Lim,T	Time to Suboptimal Treatment Patterns Among PWH on Antiretroviral Therapy in the United States
Moderated ePoster MeP05.4	Jarrett,J	ART Persistence Among Treatment- Experienced People with HIV and Mental Health Disorders in the US
BIC/LEN
Moderated ePoster MeP10.2	D’Antoni,ML	High In Vitro Resistance Barrier for the BIC/LEN Combination
ePoster eP128	Orkin,C	Demographic and Clinical Characteristics of Phase 3 Participants in ARTISTRY-1, An Open- Label Study Comparing a BIC/LEN STR With Complex ART Regimens
ePoster eP.LB006	Arora,P	DDI Liability of BIC and LEN Compared With Commonly Used Components of Complex ART Regimens in ARTISTRY-1
ISL/LEN
Oral PS15.5LB	Colson,A	Oral Weekly ISL/LEN in VS PWH: 96 Week Outcomes from a Phase 2 Study
ePoster eP133	Sali,AP	Patient-Reported Outcomes From PWH Receiving Once-Weekly Oral ISL/LEN: Phase 2 Week 48 Results
LEN + TAB + ZAB
Oral PS09.2	Ogbuagu,O	Efficacy and Safety of a Twice-Yearly Regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 Results
OTHER
ePoster eP340	Vimont,A	Costs Associated With PWH in France
HIV CURE
Oral PS07.1	Dong,K	Safety and Analytical Treatment Interruption Outcomes in a Clinical Trial of 2 Broadly Neutralizing Antibodies Plus Vesatolimod in Early-Treated South African Women With Clade C HIV-1

Locally Supported Studies: EACS 2025

B/F/TAF
ePoster eP070	Antinori,A	Effectiveness of switching to B/F/TAF from NNRTI-based ART in VS PWH: A Retrospective Analysis (DRIVE-SWITCH Study)
ePoster eP138	Schäfer,G	Physician Specialties Involved in Prescribing B/F/TAF and Concomitant Drugs in PWH in Germany: Implications for Potential DDI
ePoster eP069	Akalin,H	Effectiveness and Tolerability of B/F/TAF in PWH in Routine Clinical Practice in Türkiye: 12- month Outcomes From the KLIMIK HIV TR cohort
ePoster eP075	Ollala, J	Impact of ART Regimen Initiation or Switch in VS PWH on Lipid Profile at 48 weeks: A Systematic Literature Review
HIV TREATMENT - OTHER
Oral PS12.1	Protopapas,K	Public Knowledge, Views, Perceptions and Attitudes towards HIV and PWH in Europe - Combined Results of an HIV Public Opinion Survey Conducted in 11 European Countries

Investigator-Sponsored Research and Collaborative Studies: EACS 2025

B/F/TAF
ePoster eP158	Marcelin, A	Selection of Antiretroviral Resistance in Treatment-Experienced PWH with Virological Failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study
Oral O1.3	Miranda, MNS	Mapping Patterns of Resistance to 2nd Generation INSTI in Clinical Practice: Results From the ROSETTA-Registry
ePoster eP091	Tavelli, A	Long-term Effectiveness of B/F/TAF as Switch Strategy in VS PWH Across Age Strata: Real- Life Data From The ICONA-BIC Study
BIC/LEN
ePoster eP053	Elion, R	Characteristics and Outcomes of PWH Virally Suppressed on Complex Regimens
LEN for HTE PWH
Oral PS09.3	Charpentier,C	A French National Real-World Observatory of People Initiating A Lenacapavir-Based Treatment During The Post-Approval Period
ePoster eP101	Palich, R	Real World Use of Lenacapavir in France: A National, Observational Study
HIV TREATMENT - OTHER
ePoster eP257	Esser, S	Effect of Extreme Weight Gain Within 5 Years in PWH on Upcoming Incident Diabetes Mellitus
ePoster eP256	Esser, S	Effect of Extreme Weight Gain Within 5 Years in PWH on Upcoming Incident Cardiovascular Events
ePoster eP418	Rockstroh,JK	Estimating The Health Impact and Cost- Effectiveness of Emergency Department Opt- Out Testing For Blood-Borne Viruses in Germany

EACS 2025 Publikationen - ViiV

CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment
The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC Celia Jonsson-Oldenbüttel et al. - Oral Presentation	View Poster
Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living with HIV-1: A Meta-Analysis of Real-World Evidence Chloe Orkin et al. - ePoster	View Poster
Real-World Utilization of Cabotegravir/Rilpivirine Long-Acting Injectable: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada Joann K Ban et al. - ePoster	View Poster
High Effectiveness and Rare Virologic Failure in Treatment-Experienced Individuals on Long-Acting Cabotegravir + Rilpivirine Therapy Across Europe: Insights from the EuroSIDA Study Lars Peters et al. - ePoster	View Poster
DOLUTEGRAVIR-based regimens
PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis Paul O’Brien et al. - ePoster	View Poster
The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV María J Pérez-Elías et al. - ePoster	View Poster
Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The “AReTi” Study Results Vasileios Papastamopoulos et al. - ePoster	View Poster
CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France P. Philibert et al. - ePoster	View Poster
TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in treatment-experienced people living with HIV in TURKIYE Ayşe Deniz Gökengin et al. - ePoster	View Poster

*denotes ViiV-supported investigator led and collaborative studies

EACS 15-18. Oktober in Paris

Slides und Poster Gilead Slides und Poster ViiV

Gilead-initiated or Gilead-supported Abstracts Published at EACS 2025

Locally Supported Studies: EACS 2025

Investigator-Sponsored Research and Collaborative Studies: EACS 2025

EACS 2025 Publikationen - ViiV

Meldungen

HIV-Therapie

Baylisascaris procyonis

Influenza

Infocenter

Antibiotikaresistenz

Nachruf

Newsletter Infection&more online

HIV-Infektion

β-Lactam-Antibiotika

Mikrobe des Jahres 2026

Harnwegsinfektion

Oroya-Fieber

HIV-PrEP

MPOX

Gonorrhoe

Listeriose

Gürtelrose

Ältere Meldungen